Regeneron stock hits a 52-week high as earnings surge 70%, revenue jumps 36% and key drugs deliver r

Sanofi NASDAQ: SNY reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, sup

Sanofi SA (NASDAQ:SNY) on Friday reported third-quarter sales of $16.623 billion (14.444 billion eur

Sanofi beats Q3 earnings consensus on Dupixent growth, raises 2026 guidance, and outlines long-term

A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a st

SNY beats Q3 earnings and sales estimates as Dupixent drives growth and the company raises its 2026

Sanofi (NASDAQ:SNY) reported quarterly earnings of $2.04 per share which beat the analyst consensus

The French drugmaker is moving to fill its medicine pipeline to prepare for the looming patent expir

ExxonMobil headlines Friday’s reports, with investors watching whether strong energy production can

Novavax (NASDAQ:NVAX) has earned a $125 million milestone payment with the initiation (fifth patient

Regeneron (NASDAQ:REGN | REGN Price Prediction) reports third-quarter results on Oct. 30. Regeneron

Sanofi has increased its dividend for 31 consecutive years. It's only because this is not an America

France's 10-year government bond yield crossed 5% for the first time since 2002 and briefly topp

Sanofi is deeply undervalued, trading at 8.4x P/E despite AA rating, robust balance sheet, and a 5.8

CAMBRIDGE, England--(BUSINESS WIRE)--ScionxBio (the “company”, operating as a brand identity of Elev

In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic impr

Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a f

Sanofi's CirCLIQ® Injector, developed using enFuse technology, has been approved to administer Sarcl

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Fra

Recursion Pharmaceuticals shares rise 0.24% after hours following a $200 million stock offering and

Sanofi settles EU antitrust probe over rival flu vaccine Fluad, agreeing to binding promotional rule

Sanofi today announced the successful completion of negotiations between the pan-Canadian Pharmaceut

Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi's development

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development CandidateOn Octob

Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie

Sanofi's offer to rectify the potential effects of its past messages on a rival flu shot awould addr

Sanofi (NASDAQ: SNY - Get Free Report) and Scilex (NASDAQ: SCLX - Get Free Report) are both healthca

This article is part of our monthly series where we highlight five large-cap, relatively safe, divid

Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announc

Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewa

NEW YORK--(BUSINESS WIRE)--Weitz & Luxenberg, which represents more people in the Dupixent litigatio

The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA C

SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammatio

Regeneron and Sanofi expand their 20-year antibody collaboration with a $1 billion upfront payment a

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regenero

Sanofi (NASDAQ:SNY) reported second-quarter financial results on Thursday. The transcript from the c

Novo Nordisk taps Anthropic AI to speed medicine research, enhance software workflows, and implement

The $925 million (CAD) expansion is adding end-to-end vaccine manufacturing capacity on Canadian soi

Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutini

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligi

Oz says the MMR vaccine is “not a lethal vaccine” after Trump warned the combined shot could be “qui

Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved

President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11

https://youtu.be/H_RititNE8U

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the d

Sanofi (SNY) Q2 sales hit $13.48B, beating estimates driven by Dupixent's 37.6% surge. Full deta

Sanofi (NASDAQ:SNY) reported quarterly earnings of $1.21 per share which beat the analyst consensus

Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety da

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri

FDA approves Sanofi’s Sarclisa Escena, the first subcutaneous multiple myeloma treatment administere